Medicinova Inc (MNOV) Actualités

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

LA JOLLA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on...

Current Report Filing (8-k)

MEDICINOVA INC DE false 0001226616 0001226616 2023-06-15 2023-06-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Current Report Filing (8-k)

false0001226616MEDICINOVA INC00012266162023-06-132023-06-13   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

LA JOLLA, Calif., May 14, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on...

Quarterly Report (10-q)

falseOne Yearhttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent0001226616Q1--12-31http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrentOne...

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

LA JOLLA, Calif., April 30, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on...

Current Report Filing (8-k)

MEDICINOVA INC DE false 0001226616 0001226616 2023-04-20 2023-04-20     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...

Annual Report to Security Holders (ars)

Additional Proxy Soliciting Materials (definitive) (defa14a)

  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A...

Proxy Statement (definitive) (def 14a)

  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A...

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on...

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

LA JOLLA, Calif., Feb. 20, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on...

Annual Report (10-k)

1falseP7Y3http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent0001226616P1Y1http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrentFY3P1Y00012...